It's 3am in the morning, and I can not get back to sleep.

At 2 o'clock the alarm had to be set to give my baby an antibiotic. The sound of alarm shook me to the core. And now I am awake. This usually happens if I've gotten at least two hours of sleep.

After tossing and turning for nearly an hour, I decided to go downstairs and put on a pot of tea. I looked in the pantry and found exactly what I was searching for:

There are three tea bags left.

On the back of the box is a quote by Diane Loomans, author of The Laughing Classroom: Everyone's Guide to Teaching With Humor and Play from another one of her books, Full Esteem Ahead. Looman says:

Calling all insomniacs!

If a drug-free program of healthy sleep patterns, as a result of biofeedback, relaxation, positive thinking, and good habits is not getting you the deep sleep you need and want, there is good news to report this week.

A novel sleep therapy called Rozerem, otherwise known as Ramelteon (its chemical name), has been approved by the U.S. Food & Drug Administration (FDA).

On Friday, July 22nd 2005, Takeda Pharmaceuticals, based in Lincolnshire, Ill., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd., Japan's largest pharmaceutical company, received FDA approval for the first prescription sleep aid created that is not designated as a controlled substance.

The insomnia pill, to be marketed as Rozerem, targets only the part of the brain that regulates sleep. The chemical compound, ramelteon, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain.

Takeda's therapy induces what is very similar to natural sleep, the drug maker said.

The FDA approval allows doctors to prescribe the 8-milligram tablets for long-term use in adults, Takeda said in a statement.

Rozerem is the first prescription insomnia medication with a novel therapeutic mechanism of action in thirty-five years.

The therapy has shown no evidence of abuse or dependence.